An2 Therapeutics Inc (ANTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 21,351 | 33,504 | 26,769 | 24,693 | 15,647 |
| Marketable Securities | 62,267 | 59,922 | 77,771 | 89,517 | 91,648 |
| TOTAL | $86,262 | $97,689 | $107,438 | $116,313 | $110,507 |
| Non-Current Assets | |||||
| Investments And Advances | 5,021 | 0 | 0 | 3,904 | 27,194 |
| Other Non-Current Assets | 804 | 0 | 1,043 | 1,043 | 1,043 |
| TOTAL | $5,825 | $N/A | $1,043 | $4,947 | $28,237 |
| Total Assets | $92,087 | $97,689 | $108,481 | $121,260 | $138,744 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 3,317 | 1,711 | 1,885 | 2,433 | 2,676 |
| Accrued Expenses | 6,130 | 7,031 | 7,683 | 7,909 | 10,699 |
| Other current liabilities | 791 | 1,275 | 559 | 321 | 668 |
| TOTAL | $10,238 | $10,017 | $10,127 | $10,663 | $14,043 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $10,238 | $10,017 | $10,127 | $10,663 | $14,043 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 30,099 | 29,879 | 29,842 | 29,829 | 29,770 |
| Retained earnings | -205,776 | -198,254 | -185,507 | -171,072 | -154,455 |
| Other shareholders' equity | 31 | 112 | -27 | 53 | 275 |
| TOTAL | $81,849 | $87,672 | $98,354 | $110,597 | $124,701 |
| Total Liabilities And Equity | $92,087 | $97,689 | $108,481 | $121,260 | $138,744 |